Transcription
Sylvain Sachot 0:00
We are lucky this afternoon to have a list of several medtech companies that will that will come here to speak to tell us about their stories, companies in the field of thrombectomy, surgery, fertility and others. But before we start with pitches, just a few words about myself and about my company. I'm a partner at Asabys Partners. We are a VC firm based here in in the beautiful city of Barcelona. We've been active for the last five years or so six years. We are right now investing from our second fund. The Asabys Fund II. that's a fund that we're still fundraising but with a target of 150 million euros we have 100 million already in the bank. We've done a series of investments from fund I and from fund II between biopharma med tech diagnostics and digital. We've done quite a few investments in medtech traditional type of medtech between cardiovascular catheters pain management, digital health, we've done diagnostics in sepsis. We've done a whole bunch of of different technologies, we're still investing in them. We're still looking for for new investments. And maybe hopefully we'll find some some investments here today this afternoon. Without any further ado, let me introduce you to the first to the first speaker
Partner at Asabys, Sylvain joined the firm in 2018 from Ysios Capital. At Asabys, Sylvain is involved in the sourcing, execution, and management of our investments in the biopharma and medtech segments. He currently serves on the board of directors of Anaconda and is an observer on the boards of Inbrain Neuroelectronics, SpliceBio and Medlumics.
Previously, Sylvain spent a decade in academic labs both in France and the US, working specifically in the fields of gene therapy and regenerative medicine. He was a postdoctoral fellow in the department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine in New York following the completion of his doctoral thesis at INSERM.
Sylvain obtained his Ph.D. in Molecular Medicine from University of Nantes, holds a master’s degree in biotechnology with honors from University Paris XII, and an MBA from Esade Business School in Barcelona.
Partner at Asabys, Sylvain joined the firm in 2018 from Ysios Capital. At Asabys, Sylvain is involved in the sourcing, execution, and management of our investments in the biopharma and medtech segments. He currently serves on the board of directors of Anaconda and is an observer on the boards of Inbrain Neuroelectronics, SpliceBio and Medlumics.
Previously, Sylvain spent a decade in academic labs both in France and the US, working specifically in the fields of gene therapy and regenerative medicine. He was a postdoctoral fellow in the department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine in New York following the completion of his doctoral thesis at INSERM.
Sylvain obtained his Ph.D. in Molecular Medicine from University of Nantes, holds a master’s degree in biotechnology with honors from University Paris XII, and an MBA from Esade Business School in Barcelona.
Transcription
Sylvain Sachot 0:00
We are lucky this afternoon to have a list of several medtech companies that will that will come here to speak to tell us about their stories, companies in the field of thrombectomy, surgery, fertility and others. But before we start with pitches, just a few words about myself and about my company. I'm a partner at Asabys Partners. We are a VC firm based here in in the beautiful city of Barcelona. We've been active for the last five years or so six years. We are right now investing from our second fund. The Asabys Fund II. that's a fund that we're still fundraising but with a target of 150 million euros we have 100 million already in the bank. We've done a series of investments from fund I and from fund II between biopharma med tech diagnostics and digital. We've done quite a few investments in medtech traditional type of medtech between cardiovascular catheters pain management, digital health, we've done diagnostics in sepsis. We've done a whole bunch of of different technologies, we're still investing in them. We're still looking for for new investments. And maybe hopefully we'll find some some investments here today this afternoon. Without any further ado, let me introduce you to the first to the first speaker
Market Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy